Clinical Pharmacokinetics of Allopurinol

Clinical Pharmacokinetics

Volumn 11, Issue 5, 1986, Pages 343-353

  Murrell, G A C ^a,b   Rapeport, W G ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; MERCAPTOPURINE; OXIPURINOL;

ANIMAL EXPERIMENT; BLOOD AND HEMOPOIETIC SYSTEM; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPARISON; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG THERAPY; DRUG TOXICITY; HEART; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; LARGE INTESTINE; LIVER; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SMALL INTESTINE; SURVEY; THERAPY;

ALLOPURINOL; DISEASE; DRUG INTERACTIONS; HUMAN; KINETICS; SUPPORT, NON-U.S. GOV'T;

EID: 0022449609     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198611050-00001     Document Type: Review

References (38)

1. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration
2. The effect of dietary protein on the clearance of allopurinol and oxypurinol
3. Identification of hypoxanthine transport and xanthine oxidase activity in brain capillaries
4. Allopurinol and cytotoxic drugs
5. The enzymology of feedback inhibition of glutamine phosphoribosylpyrophosphate amidotransferase by purine nucleotides
6. Bioavailability of allopurinol oral and rectal dosage forms
7. Enhanced purine salvage during allopurinol therapy: an important pharmacologic property in humans
8. Studies with allopurinol in patients with impaired renal function
9. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase
10. Renal clearance of oxypurinol, the chief metabolite of allopurinol
11. Hochdruckflussigchromatographische bestimmung von allopurinol und oxypurinol in serum
12. Panztopenie nach kombinationsbehandlung mit allopurinol und azothioprin
13. A competitive protein binding assay for allopurinol and oxipurinol
14. Severe allopurinol toxicity. Description and guidelines for patients with renal insufficiency
15. Allopurinol kinetics
16. Cerebrospinal fluid versus serum concentrations of 3-FU, allopurinol, and oxipurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation
17. Vergleichende prufung der bioverfugbarkeit und des pharmakodynamischen effektes von funf allopurinol-zubereitungen
18. Localisation of xanthine oxidase in mammary-gland epithelium and capillary endothelium
19. Allopurinol: alteration in pyrimidine metabolism in man
20. Apparent metabolism of allopurinol by blood
21. The bioavailability of two commercial preparations of allopurinol tablets
22. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
23. 14C]oxipurinol in rat tissues and effects on uridine nucleotide pool
24. Allopurinol absorption from different sites of the rat gastrointestinal tract
25. Behaviour of chlorpropamide in renal insufficiency and under the effects of associated drug therapy
26. The effect of 6-mercaptopurine and allopurinol on granulopoiesis
27. Effects of xanthine oxidase inhibition of thiopurine metabolism, hyperuricemia and gout
28. Variations in allopurinol metabolism by xanthinuric subjects
29. Analysis of allopurinol and oxypurinol in plasma and its application to metabolic studies
30. Quantitation of oxypurines and allopurinol metabolites in biological fluids by cation exchange chromatography
31. Impairment of drug metabolism in man by allopurinol and nortriptyline
32. Metabolic and therapeutic effects of allopurinol in patients with leukaemia and gout
33. Verlauf der oxipurinolspeigel im plasma nach akuter und chronischer gabe von allopurinol in verschiedenen zubereitunger
34. Potentiation of an effect of allopurinol on pyrimidine metabolism by chlorothiazide in man
35. Phenytoin-allopurinol interaction: Michaelis-Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch-Nyhan syndrome
36. Severe allopurinol sensitivity: association with thiazides and prior renal compromise
37. Inhibition of first pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol